ChiCTR2300071848: A Randomized, Double-blind, Placebo-Controlled Study in China to evaluate the efficacy and safety of VGX-3100 Delivered Intramuscularly (IM) followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix |
|
|
| Recruiting | 3 | 84 | | 6 mg (1 ml) VGX-3100 intramuscular injection followed by EP with the CELLECTRA 5PSP device given at Day 1, Week 4 and Week 12 ;Placebo intramuscular injection followed by EP with the CELLECTRA 5PSP device given at Day 1, Week 4 and Week 12 | Chinese Academy of Medical Sciences Cancer Hospital; Beijing Apollo Saturn Biomedicine Technology Co. LTD, Beijing Apollo Saturn Biomedicine Technology Co. LTD | High Grade Squamous Intraepithelial Lesion of the Cervix | | | | |
NCT03603808: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions |
|
|
| Active, not recruiting | 2 | 80 | US | Electroporation, electroporation therapy, EPT, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, VGX-3100, Laboratory Biomarker Analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Inovio Pharmaceuticals | Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | 09/29 | 09/29 | | |
